Linked Life Data

48887BiochemicalReaction1808

Source:http://www.reactome.org/biopax/48887BiochemicalReaction1808

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
biopax3:comment
Authored: Rothfels, K, 2012-02-09, Edited: Rothfels, K, 2012-05-16, Reviewed: Ezzat, S, 2012-05-15, Treatment of FGFR1-amplified lung and breast cancer cell lines with the in vitro reagents PD173704, SU5402 and FIIN-1 inhibits proliferation, while cells expressing wild-type levels of FGFR1 are insensitive to inhibitors, suggesting that amplified FGFR1 may be a suitable therapeutic target in some cancer lines (Weiss, 2010; Reis-Filho, 2006; Dutt, 2011; Turner, 2010). In fact, a number of other small molecule inhibitors, including Dovitinib and AZD4547, are currently in clinical trials for treatment of FGFR1-amplified cancers (reviewed in Turner and Grose, 2010; Wesche, 2011; http://ClinicalTrials.gov)
biopax3:xref
biopax3:dataSource
biopax3:displayName
Tyrosine kinase inhibitors bind and inhibit overexpressed FGFR1 dimers
biopax3:left
biopax3:participantStoichio...
biopax3:right